Screening for Clonal Hematopoiesis for Mitigating the Risk of Hematopoietic Neoplasms after PRRT

Piyush Chandra; Kishore Kumar

doi:10.1055/s-0043-1764308

World Journal of Nuclear Medicine, Inhaltsverzeichnis

CC BY 4.0 · World J Nucl Med 2023; 22(02): 150-151
DOI: 10.1055/s-0043-1764308

Letter to the Editor

Screening for Clonal Hematopoiesis for Mitigating the Risk of Hematopoietic Neoplasms after PRRT

Piyush Chandra

¹Department of Nuclear Medicine, Zydus Hospitals, Vadodara, Gujarat, India

,

Kishore Kumar

²Department of Hematology, MIOT International, Chennai, Tamil Nadu, India

References
1 Strosberg J, El-Haddad G, Wolin E. et al; NETTER-1 Trial Investigators. Phase 3 trial of ¹⁷⁷Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (02) 125-135
2 Vigne J, Chrétien B, Bignon AL, Bouhier-Leporrier K, Dolladille C. [¹⁷⁷Lu]Lu-DOTATATE peptide receptor radionuclide therapy-associated myeloid neoplasms: insights from the WHO pharmacovigilance database. Eur J Nucl Med Mol Imaging 2022; 49 (10) 3332-3333
3 Kwekkeboom DJ, de Herder WW, Kam BL. et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26 (13) 2124-2130
4 Imhof A, Brunner P, Marincek N. et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011; 29 (17) 2416-2423
5 Bodei L, Kidd M, Paganelli G. et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 2015; 42 (01) 5-19
6 Sabet A, Ezziddin K, Pape UF. et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med 2013; 54 (11) 1857-1861
7 Brabander T, van der Zwan WA, Teunissen JJM. et al. Long-term efficacy, survival, and safety of [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res 2017; 23 (16) 4617-4624
8 Strosberg JR, Caplin ME, Kunz PL. et al; NETTER-1 investigators. ¹⁷⁷Lu-Dotatate plus long-acting octreotide versus high–dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021; 22 (12) 1752-1763
9 Brieau B, Hentic O, Lebtahi R. et al. High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy. Endocr Relat Cancer 2016; 23 (05) L17-L23
10 Goncalves I, Burbury K, Michael M. et al. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. Eur J Nucl Med Mol Imaging 2019; 46 (09) 1902-1910
11 Garske-Román U, Sandström M, Fröss Baron K. et al. Prospective observational study of ¹⁷⁷Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging 2018; 45 (06) 970-988
12 Coombs CC, Zehir A, Devlin SM. et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 2017; 21 (03) 374-382.e4
13 Singh A, Mencia-Trinchant N, Griffiths EA. et al. Mutant PPM1D- and TP53-driven hematopoiesis populates the hematopoietic compartment in response to peptide receptor radionuclide therapy. JCO Precis Oncol 2022; 6: e2100309
14 Bolton KL, Gillis NK, Coombs CC. et al. Managing clonal hematopoiesis in patients with solid tumors. J Clin Oncol 2019; 37 (01) 7-11